WO2026072455A1 - Anticorps à domaine unique ciblant l'albumine sérique humaine - Google Patents

Anticorps à domaine unique ciblant l'albumine sérique humaine

Info

Publication number
WO2026072455A1
WO2026072455A1 PCT/US2025/047117 US2025047117W WO2026072455A1 WO 2026072455 A1 WO2026072455 A1 WO 2026072455A1 US 2025047117 W US2025047117 W US 2025047117W WO 2026072455 A1 WO2026072455 A1 WO 2026072455A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
variant
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/047117
Other languages
English (en)
Inventor
William Winston
Tiziana CAFARELLI
Celesztina Diana NAGY-DOMONKOS
Jose Andres SALMERON-GARCIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Werewolf Therapeutics Inc
Original Assignee
Werewolf Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werewolf Therapeutics Inc filed Critical Werewolf Therapeutics Inc
Publication of WO2026072455A1 publication Critical patent/WO2026072455A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des sdAb qui présentent une spécificité de liaison ciblant l'albumine sérique humaine comprenant un CDR1, un CDR2 et un CDR3. L'invention concerne également des protéines de fusion, des conjugués, des cytokines à demi-vie prolongée et des promédicaments de cytokine inductibles comprenant le sdAb.
PCT/US2025/047117 2024-09-26 2025-09-19 Anticorps à domaine unique ciblant l'albumine sérique humaine Pending WO2026072455A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202463699305P 2024-09-26 2024-09-26
US202463699291P 2024-09-26 2024-09-26
US202463699262P 2024-09-26 2024-09-26
US63/699,305 2024-09-26
US63/699,291 2024-09-26
US63/699,262 2024-09-26
US202463704207P 2024-10-07 2024-10-07
US63/704,207 2024-10-07

Publications (1)

Publication Number Publication Date
WO2026072455A1 true WO2026072455A1 (fr) 2026-04-02

Family

ID=97447071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/047117 Pending WO2026072455A1 (fr) 2024-09-26 2025-09-19 Anticorps à domaine unique ciblant l'albumine sérique humaine

Country Status (1)

Country Link
WO (1) WO2026072455A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
WO2006110728A2 (fr) 2005-04-12 2006-10-19 The Uab Research Foundation Agregats de tegument immunogenes
US20170369563A1 (en) * 2016-05-20 2017-12-28 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
WO2019222296A1 (fr) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 12 activables et procédés d'utilisation associés
WO2019222295A1 (fr) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 2 activables et procédés d'utilisation associés
WO2020232305A1 (fr) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Groupes caractéristiques de séparation, procédés et utilisation associés
WO2021097376A1 (fr) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Polypeptides de cytokine activables et leurs méthodes d'utilisation
WO2021236676A1 (fr) 2020-05-19 2021-11-25 Werewolf Therapeutics, Inc. Polypeptides il-12 activables et leurs procédés d'utilisation
WO2023060242A1 (fr) * 2021-10-08 2023-04-13 Werewolf Therapeutics, Inc. Promédicament d'il-2
WO2025072443A2 (fr) * 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Polypeptides il-21 activables et leurs procédés d'utilisation et anticorps d'albumine sérique humaine à domaine unique
WO2025151274A1 (fr) * 2024-01-08 2025-07-17 Adimab, Llc Promédicaments d'il-18 inductibles

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
WO2006110728A2 (fr) 2005-04-12 2006-10-19 The Uab Research Foundation Agregats de tegument immunogenes
US20170369563A1 (en) * 2016-05-20 2017-12-28 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
WO2019222296A1 (fr) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 12 activables et procédés d'utilisation associés
WO2019222294A1 (fr) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides de cytokine activables et leurs procédés d'utilisation
WO2019222295A1 (fr) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Polypeptides d'interleukine 2 activables et procédés d'utilisation associés
WO2020232305A1 (fr) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Groupes caractéristiques de séparation, procédés et utilisation associés
WO2021097376A1 (fr) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Polypeptides de cytokine activables et leurs méthodes d'utilisation
WO2021236676A1 (fr) 2020-05-19 2021-11-25 Werewolf Therapeutics, Inc. Polypeptides il-12 activables et leurs procédés d'utilisation
WO2023060242A1 (fr) * 2021-10-08 2023-04-13 Werewolf Therapeutics, Inc. Promédicament d'il-2
WO2025072443A2 (fr) * 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Polypeptides il-21 activables et leurs procédés d'utilisation et anticorps d'albumine sérique humaine à domaine unique
WO2025151274A1 (fr) * 2024-01-08 2025-07-17 Adimab, Llc Promédicaments d'il-18 inductibles

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
ALLEN ET AL., LIFE, vol. 11, no. 6, 2021, pages 465
BRINKMAN ET AL., J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186
BURTON ET AL., ADVANCES IN IMMUNOLOGY, vol. 57, 1994, pages 191 - 280
CHAUDHURY ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 197, no. 3, 2003, pages 315 - 322
COFFIN ET AL.: "Retroviruses", 1997, COLD SPRING HARBOR LABORATORY PRESS
DAVIDSON ET AL., J. VIROL., vol. 61, 1987, pages 1226 - 39
FREJD ET AL., EXP MOLMED., vol. 49, no. 3, 2017, pages c306
GARCEAGISSMANN, CURRENT OPINION IN BIOTECHNOLOGY, vol. 15, 2004, pages 513 - 7
HAJ-AHMAD ET AL., J. VIROL., vol. 57, 1986, pages 267 - 74
HARLOW ET AL.: "Antibodies: A Laboratory Manual", 2014, COLD SPRING HARBOR LABORATORY
HOEFINAN ET AL., ANTIBODIES, vol. 4, no. 3, 2015, pages 141 - 156
KETTLEBOROUGH ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958
KOHLER ET AL., EUR. J. IMMUNOL., vol. 6, 1976, pages 511 - 519
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
MADAN ET AL., BLOOD, vol. 138, no. 1, 2021, pages 1654
MASSIC ET AL., MOL. CELL. BIOL., vol. 6, 1986, pages 2872 - 83
MESTER ET AL., MABS, vol. 13, no. 1, 2021, pages 1893888
MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 550 - 552
PEPPERL-KLINDWORTH ET AL., GENE THERAPY, vol. 10, 2003, pages 278 - 84
PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18
PETERS, ADV. PROTEIN CHEM., 1985, pages 161 - 245
PLUCKTHUN ET AL., ANN. REV. OF PHARMACOLOGY AND TOXICOLOGY, vol. 55, 2015, pages 489 - 511
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
SHEN ZHUOLUN ET AL: "A resource of high-quality and versatile nanobodies for drug delivery A resource of high-quality and versatile nanobodies for drug delivery", CELL PRESS, 24 September 2021 (2021-09-24), pages 1 - 26, XP055972998, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/318494/1-s2.0-S2589004221X00090/1-s2.0-S2589004221009822/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEG0aCXVzLWVhc3QtMSJHMEUCICknF4Y7j2g+sftYMst9Nuno6Wlw+eNc9iV7koKPYKcKAiEA3PbweicNJbV+jgq/rGW+PThtLYVSHM2gb0Yaj5993oUqzAQIRhAFGgwwNTkwMDM1NDY4NjUiDLfQk9KwHZydKWk0t> *
WALDMAN ET AL., PROG ALLERGY, vol. 13, 1969, pages 1 - 110
WARD ET AL., ADV. IMMUNOL., vol. 103, 2009, pages 77 - 115
ZHANG ET AL., BIOTECHNIQUES, vol. 15, 1993, pages 868 - 72

Similar Documents

Publication Publication Date Title
US11912773B2 (en) Fc variants and methods for their production
KR102511268B1 (ko) Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
TWI767899B (zh) Psma及cd3雙特異性t細胞嚙合抗體構築體
KR102688969B1 (ko) Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
EP2670776B1 (fr) Variantes génétiques de fc et leurs procédés de production
JP2020122013A (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
EP4347655A1 (fr) Anticorps anti-ccr8 et leurs utilisations
JP2019151634A (ja) 二重特異性二価ｓｃＦｖ−Ｆｃ分子
EP3023437A1 (fr) Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3928790A1 (fr) Fragment de liaison à l&#39;antigène cd3 et application de celui-ci
KR20180033501A (ko) Dll3 및 cd3에 결합하는 이중특이적인 항체 작제물
US20240392003A1 (en) Multispecific antibodies having specificity for ror1 and cd3
HK1212362A1 (en) Coiled coil and/or tether containing protein complexes and uses thereof
JP2016513467A (ja) ヘテロ二量体性二重特異性抗体
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
CN105555803A (zh) 制瘤素m受体抗原结合蛋白
CN118317978A (zh) 结合nkg2d、cd16和baff-r的蛋白
CN115894701A (zh) 结合cd3的抗体及其用途
CN118317975A (zh) 靶向baff-r的抗体及其用途
KR20240049318A (ko) Fap/cd40 결합 분자 및 이의 의학적 용도
KR20230166120A (ko) 새로운 tnfr2 결합 분자
WO2025072443A2 (fr) Polypeptides il-21 activables et leurs procédés d&#39;utilisation et anticorps d&#39;albumine sérique humaine à domaine unique
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
WO2025151274A1 (fr) Promédicaments d&#39;il-18 inductibles
WO2026072455A1 (fr) Anticorps à domaine unique ciblant l&#39;albumine sérique humaine